Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status
暂无分享,去创建一个
Jiyan Liu | H. Dong | D. Cao | Ye Chen | Yuan Tang | K. Cheng | Long-Hao Li | J. Ge | Xing-chen Peng | Xing-Chen Peng | Hang Dong
[1] Rahul Bhagat,et al. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development , 2012, Cellular Oncology.
[2] A. Kittai,et al. Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer , 2012, Chemotherapy research and practice.
[3] M. Arends,et al. RAS signalling in the colorectum in health and disease , 2012, Cell communication & adhesion.
[4] Seon Ho Park,et al. RASSF1A suppresses the activated K-Ras-induced oxidative DNA damage. , 2011, Biochemical and biophysical research communications.
[5] T. Motoyama,et al. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. , 2011, Anticancer research.
[6] Gang Wu,et al. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma , 2009, Journal of experimental & clinical cancer research : CR.
[7] Shuji Ogino,et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.
[8] R. Lothe,et al. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. , 2008, Neoplasia.
[9] Dong Sun Kim,et al. Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer. , 2007, Molecules and cells.
[10] M. Lerman,et al. Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage. , 2007, Cancer letters.
[11] H. Donninger,et al. The RASSF1A tumor suppressor , 2007, Journal of Cell Science.
[12] L. Hesson,et al. The Role of RASSF1A Methylation in Cancer , 2007, Disease markers.
[13] M. Roncalli,et al. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer , 2006, British Journal of Cancer.
[14] K. Hatakeyama,et al. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[15] Miki Ohira,et al. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. , 2006, Oncology reports.
[16] R. Cohen,et al. Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep , 2005 .
[17] Jing-Yuan Fang,et al. The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.
[18] G. Pfeifer,et al. Methylation of the Tumor Suppressor Gene RASSF1A in Human Tumors , 2005, Biochemistry (Moscow).
[19] W. Yeo,et al. High frequency of promoter hypermethylation of RASSF1A in tumorous and non‐tumourous tissue of breast cancer , 2005, Pathology.
[20] K. Hatakeyama,et al. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. , 2004, Human pathology.
[21] Y. Shim,et al. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. , 2003, Cancer research.
[22] G. Pfeifer,et al. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. , 2003, Cancer research.
[23] R. Labianca,et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] A. Protopopov,et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. , 2002, Cancer research.
[25] S. Chi,et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.
[26] N. Goldstein,et al. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.
[27] J. Minna,et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.
[28] A. Bell,et al. Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis* , 2000, The Journal of Biological Chemistry.
[29] M. Barbacid,et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. , 1984, Science.
[30] L. Hesson,et al. The role of RASSF 1 A methylation in cancer , 2014 .
[31] O. Olopade,et al. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. , 2008, Cancer research.
[32] J. Herman,et al. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] J. Herman,et al. RASSF 1 A methylation and Kras and B-raf mutations and recurrent endometrial cancer , 2007 .
[34] A. Protopopov,et al. The RASSF 1 A Tumor Suppressor Gene Is Inactivated in Prostate Tumors and Suppresses Growth of Prostate Carcinoma Cells 1 , 2002 .
[35] M. Ohira,et al. Aberrant methylation of RASGRF 2 and RASSF 1 A in human non-small cell lung cancer , 2022 .